Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

View all content

Pink Sheet

US Researchers Working Toward Universal Coronavirus Vaccine

By Sue Sutter 18 Feb 2020

The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.

View article
Pink Sheet

Coronavirus Supply Chain Threats Demand Coordinated Industry Response

By Bowman Cox 18 Feb 2020

Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.

View article
Pink Sheet

Coronavirus Efforts Could Benefit From Little-Used Medical Countermeasures Incentives

By Bridget Silverman 18 Feb 2020

US FDA’s Medical Countermeasures Initiative authorities like emergency use authorization have not yet had much of an impact on drugs and biologics, but agency is committed to supporting a swift response to the new strain of coronavirus.

Topic Infectious Diseases Vaccines Coronavirus

View article
Pink Sheet

For Coronavirus US FDA Is At The Podium But Not On The Task Force

By Derrick Gingery 18 Feb 2020

The FDA is curiously not one of the HHS entities coordinating the US response to the outbreak, but must monitor for manufacturing disruptions and shortages, as well as approve new treatments and diagnostics.

Topic FDA Vaccines Infectious Diseases Coronavirus

View article
Pink Sheet

Stress Test: Coronavirus Challenges China Emergency Approval Mechanism

By Brian Yang 18 Feb 2020

72 Products Approved Under Expanded Emergency Pathway A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.

View article
Pink Sheet

UK Firms Asked To Check Coronavirus Supply Chain Impact

By Ian Schofield 18 Feb 2020

Authorities Also Investing In Vaccines And Tests Amid concerns that the coronavirus outbreak could have an impact on the supply of APIs and other materials sourced from Chinese manufacturers, pharmaceutical companies are to assess their supply chain situation to help ensure patients do not experience medicine shortages.

View article
Scrip

A Positive Outlook For Deals, With Election Year Caveats

By Jessica Merrill 17 Feb 2020

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.

Topic BioPharmaceutical

View article
Scrip

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

By Kevin Grogan 17 Feb 2020

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Topic Alzheimer's Disease

View article
Generics Bulletin

Sun Finds US ‘Challenging’

By Penelope MacRae 17 Feb 2020

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends

View article
Pink Sheet

FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims

By Brenda Sandburg 17 Feb 2020

Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).

View article
Scrip

38th Annual J.P. Morgan Healthcare Conference Review

07 Feb 2020

Go inside the 2020 J.P. Morgan Healthcare Conference with exclusive reporting from Scrip. Explore the most important news from each day, and access exclusive, real-time interviews with pharma and biotech movers and shakers, and discover insights into the trends revealed at this year’s event.

Single report
Scrip

Gilead Joins Coronavirus Fray With Repurposed Antiviral

By Brian Yang 07 Feb 2020

US antiviral specialist Gilead is working to provide its experimental drug remdesivir to treat the China coronavirus, while other potential treatments and alliances continue to emerge, including between Wuhan-based BravoVax and US venture GeoVax.

Topic Coronavirus

View article
Scrip

GSK Joins Race To Tackle Coronavirus

By Kevin Grogan 07 Feb 2020

The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.

Topic Coronavirus

View article
Scrip

Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing

By Bowman Cox 07 Feb 2020

As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.

Topic Coronavirus

View article
Scrip

Coronavirus Notebook: China Generic Antiviral Filed For Emergency Approval

By Brian Yang 07 Feb 2020

China is tightening oversight over suspected coronavirus cases, allowing hospitals to quarantine patients upon their first visit as confirmed infections surpass 20,000. Domestic firm Ascletis has meanwhile filed for the emergency approval of its generic version of AbbVie's Norvir (ritonavir) and a novel combo therapy.

Topic Coronavirus

View article